Stock Watch: Pfizer’s Second-Quarter Pandemic And Base Businesses Diverge
Pfizer’s Continued COVID-19 Revenue Streams Appear Discounted
Executive Summary
Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.
You may also be interested in...
Stock Watch: Binary Second-Quarter Oncology And COVID-19 Trends
Oncology drug sales plummeted during the pandemic leading to a backlog of untreated patients that lingered even after the impact of COVID-19 drugs. While Q2 reports suggest this cancer backlog is now being addressed, the contrasting fates of vaccines and treatments for SARS-CoV-2 are actually turning out to be opaquer than expected.
Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.